Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $61.85, for a total transaction of $432,950.00. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at $2,064,367.45. The trade was a 17.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00.
• On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31.
• On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00.

Oruka Therapeutics Stock Down 3.1%

Shares of NASDAQ:ORKA opened at $61.93 on Friday. The company’s 50 day moving average price is $55.17 and its two-hundred day moving average price is $39.33. Oruka Therapeutics, Inc. has a 12-month low of $9.40 and a 12-month high of $91.00. The firm has a market cap of $3.73 billion, a PE ratio of -31.92 and a beta of -0.20.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, research analysts expect that Oruka Therapeutics, Inc. will post -2.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ORKA. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Thursday. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. UBS Group increased their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, HC Wainwright upped their price target on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $120.80.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Oruka Therapeutics by 18.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after acquiring an additional 11,205 shares during the period. Quantinno Capital Management LP bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $254,000. Atika Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $11,277,000. Sei Investments Co. lifted its holdings in shares of Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after acquiring an additional 13,164 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Oruka Therapeutics by 119.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after acquiring an additional 1,736 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.